Sign in to continue:

Friday, April 17th, 2026

Berkshire Hathaway Inc. Issues ¥272.3 Billion Senior Notes Due 2029 and 2031 – Full Terms, Underwriting Details, and Legal Agreements

Berkshire Hathaway Issues Major Yen-Denominated Senior Notes – Strategic Move in Global Debt Markets

Key Highlights from Berkshire Hathaway’s SEC Filing

  • Issuance of Yen-Denominated Senior Notes: On April 16, 2026, Berkshire Hathaway Inc. announced the issuance of a massive ¥272,300,000,000 in aggregate principal amount of senior notes. This includes four tranches:
    • ¥128,900,000,000 2.077% Senior Notes due 2029
    • ¥86,800,000,000 2.465% Senior Notes due 2031
    • ¥22,300,000,000 2.739% Senior Notes due 2033
    • ¥27,300,000,000 3.084% Senior Notes due 2036
  • Underwriting: The notes are underwritten by Mizuho Securities USA LLC and Merrill Lynch International.
  • SEC Registered Offering: The notes are issued under a SEC-registered offering, signifying full transparency and compliance with U.S. securities regulations.
  • Not Listed: The notes will not be listed on any exchange, making them private placements.
  • Global Distribution: The offering is targeted at institutional investors and professional clients, with restrictions in several jurisdictions to avoid retail exposure.

Strategic and Price-Sensitive Information for Shareholders

  • Debt Market Expansion: This is one of Berkshire Hathaway’s largest yen-denominated debt issuances, signaling a strategic expansion in global capital markets and diversification of funding sources.
  • Purpose and Use of Proceeds: The proceeds from these issuances are to be used in the manner specified in the registration statement, prospectus, and the final term sheet under “Use of Proceeds.” While specifics are not detailed in the filing, such large-scale fundraising typically supports acquisitions, refinancing, or other corporate purposes.
  • Legal and Regulatory Compliance: The offering is structured with strict compliance to U.S., Japanese, and international securities laws. There are explicit restrictions against retail sales in the EU, UK, Hong Kong, Singapore, and Japan, targeting only qualified institutional investors.
  • Material Adverse Change Statement: The company confirms there has been no material adverse change in its business, financial position, or senior management since the most recent consolidated financial statements, except as disclosed in the registration documents. This is a positive affirmation for shareholders regarding financial stability.
  • Financial Controls and Audit: Berkshire Hathaway asserts effective internal controls over financial reporting and disclosure procedures, with no material weaknesses detected. Deloitte & Touche LLP, the company’s auditor, is confirmed as an independent registered public accounting firm.
  • Indemnification and Risks: The underwriting agreement contains detailed indemnity provisions, including protection against material misstatements and omissions in offering documents, highlighting robust risk management in the issuance process.
  • Jurisdictional Restrictions: Offers and sales are restricted in certain markets, including Japan, Hong Kong, Singapore, and the UK, signifying a focus on institutional placements and limiting retail investor exposure.
  • Stabilization and Manipulation Clauses: The company and underwriters commit not to engage in stabilization or manipulation of the securities price, in accordance with EU and UK regulations.

Potential Impact on Share Price

  • Liquidity and Financial Flexibility: The ability to raise a substantial amount of capital in yen increases Berkshire Hathaway’s financial flexibility and global reach. This could be viewed positively by investors as it enables strategic investments, acquisitions, and refinancing options.
  • Currency Diversification: Yen-denominated debt may provide a hedge against currency risk and diversify the company’s debt portfolio, which is important for shareholders given Berkshire Hathaway’s global operations.
  • No Material Adverse Change: The affirmation of no material adverse changes in business or management is reassuring and reduces downside risk for investors.
  • Interest Rate Exposure: The fixed rates of the issued senior notes lock in borrowing costs, potentially benefiting Berkshire Hathaway in a rising interest rate environment.
  • Reputation and Market Access: The successful placement of such large debt in Japan and internationally underscores Berkshire Hathaway’s reputation and access to global capital, which may enhance investor confidence.

Other Notable Details

  • Documentation: The filing includes underwriting agreements, officers’ certificates, and legal opinions from Baker & McKenzie LLP and Anderson Mori & Tomotsune, confirming compliance and legal validity.
  • Management Sign-off: The filing is executed by Marc D. Hamburg, Senior Vice President and Chief Financial Officer, confirming its authenticity and importance.

Conclusion

Berkshire Hathaway’s issuance of ¥272.3 billion in yen-denominated senior notes is a significant event for investors, marking a strategic move in global debt markets. The company’s financial stability, robust controls, and targeted institutional placement of the notes are positive indicators. This event may impact share price by enhancing liquidity, financial flexibility, and global reputation. Investors should monitor subsequent disclosures regarding the use of proceeds and any strategic investments or acquisitions funded by this capital raise.


Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. All information is based on Berkshire Hathaway’s SEC filing dated April 16, 2026, and may be subject to change.

View BERKSHIRE HATHAWAY INC Historical chart here



ONE Gas, Inc. Files Form 8-K with SEC Announcing April 7, 2026 News Release and Regulatory Disclosure

ONE Gas, Inc. Schedules First Quarter 2026 Earnings Release ...

Sana Biotechnology, Inc. 2025 Annual Report: Business Overview, Risk Factors, and Strategic Pipeline Highlights

Sana Biotechnology, Inc. 2025 Annual Report: Key Investor In...